Treatment Decisions for Relapsed/Refractory Multiple Myeloma

Treatment Decisions for Relapsed/Refractory Multiple Myeloma

Fitting the Pieces Together

View Activity

Activity Features

Downloadable Slides

Activity Overview

With these downloadable slides presented at our symposium held at the 1st European Myeloma Network Meeting 2018, explore the latest updates on the treatment of patients with relapsed/refractory multiple myeloma (R/R MM) with a focus on immunotherapy along with treatment selection and sequencing in the R/R disease setting.

The information in this activity is intended for healthcare professionals based outside of the United States. You will be asked to provide your credentials before participating in the activity. This activity may contain information on products outside the approved indications where you practice.

Provider

This activity is provided by prIME Oncology.

Support

This educational activity is supported by a grant from Bristol-Myers Squibb.

Featured Expert

  • Pieter Sonneveld, MD, PhD, on behalf of Gareth Morgan, MD, PhD, FRCP, FRCPath, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

Featured Topic

Hot topic in MM: The evolving role for immunotherapy in patients with R/R disease

Learning Objectives

  • Discuss the rationale and mechanism of action for emerging immunotherapy options in the treatment of R/R MM

Featured Expert

  • Hermann Einsele, MD, Julius Maximilian University of Würzburg, Würzburg, Germany

Featured Topic

Weighing the options at first relapse

Learning Objectives

  • Evaluate recent clinical trial data investigating the efficacy and safety of novel doublet and triplet regimens and employ best practices in the selection of these regimens in the treatment of R/R MM
  • Describe the factors that influence treatment selection and sequencing in the R/R disease setting

Featured Expert

  • Meletios Dimopoulos, MD, University of Athens, Athens, Greece

Featured Topic

How do I choose? Treatment decisions after multiple lines of therapy

Learning Objectives

  • Describe the factors that influence treatment selection and sequencing in the R/R disease setting
  • Identify important ongoing clinical trials investigating novel treatment approaches for R/R MM

Featured Expert

  • Pieter Sonneveld, MD, PhD, Erasmus Medical Center Cancer Institute, Rotterdam, the Netherlands

Featured Topic

prIME Points™

Learning Objectives

  • Describe the factors that influence treatment selection and sequencing in the R/R disease setting
  • Identify important ongoing clinical trials investigating novel treatment approaches for R/R MM

ENDURING MATERIAL FROM A CERTIFIED ACTIVITY

This enduring material, derived from a certified live event, contains content that is evidence-based, balanced, and free of commercial bias. While the content was planned and implemented by prIME Oncology for a certified live event, this activity does not offer continuing education credit.

Disclosure of Relevant Financial Relationships

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Dimopoulos has disclosed he has received honoraria or consultation fees from Amgen, Celgene, Janssen, and Takeda. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Einsele has disclosed that he has received fees for grants/research support, honoraria or consultation fees, and advisory board participation from Amgen, Bristol-Myers Squibb, Celgene, and Janssen. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Morgan has no relevant financial relationship to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Sonneveld has disclosed that he has received grants/research support from Amgen, Celgene, Janssen, Karyopharm, Skyline Dx, and Takeda. He also disclosed that he has received honoraria or consultation fees from Amgen, Celgene, Janssen, Karyopharm, and Takeda. Dr Sonneveld participated in advisory boards for Amgen, Celgene, Janssen, Karyopharm, Skyline Dx, and Takeda. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The employees of prIME Oncology have disclosed:

  • Janice Galleshaw, MD (medical director content reviewer/planner) – no relevant financial relationships
  • Sanneke Koekkoek, RN (scientific content reviewer/planner) – no relevant financial relationships
  • Jessica Mastrodomenico, MPH (editorial content reviewer) – no relevant financial relationships